Already nyt article. Not good news for other generic makers
Martin shrekli ceo-founder was kicked out by retrophin had raised 90m usdusd from investors recently
long-standing criteria, which are that board
members be owner-oriented, business-savvy, interested and truly independent. I say “truly” because many
directors who are now deemed independent by various authorities and observers are far from that
2. directors “should behave as if there was a single absentee owner, whose long-term interest they
should try to further in all proper ways.”
3. “If able but greedy managers overreach
and try to dip too deeply into the shareholders’ pockets, directors must slap their hands.”
4. Charlie and I believe our four criteria are essential if directors are to do their job – which, by law,
is to faithfully represent owners.
5. It is certainly true that it is desirable to have directors
who think and speak independently – but they must also be business-savvy, interested and shareholder oriented.
In my 1993 commentary, those are the three qualities I described as essential.
6. Over a span of 40 years, I have been on 19 public-company boards (excluding Berkshire’s) and have
interacted with perhaps 250 directors. Most of them were “independent” as defined by today’s rules. But the
great majority of these directors lacked at least one of the three qualities I value. As a result, their
contribution to shareholder well-being was minimal at best and, too often, negative. These people, decent and
intelligent though they were, simply did not know enough about business and/or care enough about
shareholders to question foolish acquisitions
7. To find new directors, we will look through our shareholders list for people who directly, or in their
family, have had large Berkshire holdings – in the millions of dollars – for a long time. Individuals making
that cut should automatically meet two of our tests, namely that they be interested in Berkshire and
shareholder-oriented. In our third test, we will look for business savvy, a competence that is far from
Undervalued considering they have NDA pending , 1 phase 3 program and 1 phase 2 all addressing big markets. Fantastic buy for sun.
Sun Phrama rises 1.4 per cent to hit high of Rs 858 after Taro Keveyis drug at a high price $163.8/tablet implying annual cost of $120,000 per patient. Size of the drug depends on how many patients shift to Keveyis, every 1,000 patients shifting to Keveyis will add $120 million to gross sales. Keveyis is used to treat periodic paralysis
QST gel - testestorone replacement therapy could be a hit...the market for these gels around 700k patients in USA.
Antares is looking for a partner...taro needs to look at this opportunity
Considering how many times the timeline expectation was not met, (new p3 trial was talked abt in 2012!)
I thought this would never happen. I was proven wrong today after 3 years
Do you know the advantages in terms of efficacy, safety n tolerability of keveyis vs the other cheaper generic you mentioned. You have to think taro has done its dd before investing in this. Why is the generic not approved yet for this indication? Even though it is used off label
Note this is an orphan indication...very less competition expected if any.
Plus taro takes 100 percent of profits...no partner..
I guess to make $200m a year in USA they will need go charge 40k USD per patient per year.
Maybe another $200m from Row markets....that would be for a total of $400m per year most of which will flow to bottomline
Could be very conservativeconservative number if it can earn say $450m per year for 20 years. Now that regulatory risk is over...the only risks are new and better products....patent would be solid for 18 years preventing generics. I think NPV would be in multibillions if the average revenue would be 450m per year. It appears the pricing would be beyond 20k per patient.
Huge. Generally treatment cost will be very high for orphan diseases. Even if they get 10000 patients n per patient cost is 10000....do the numbers ...just speculating
What's the $ market potential for this orphan drug ? Is it $100m or are we talking $500m? Thank you for digging . only kal and his friend knew!
I just hope Mr. Shanghvi is mindful of the significant contribution of TARO in SUN 's unprecedent expansion (and coincidentally, his net worth) in recent years; TARO has been a significant part of SUN's EBITDA for the last 4 years and Taro's cash boosts Sun's Balance sheet . In many ways acquiring controlling stake in TARO has been game changing for SUN. Sun has been able to make 6-7 acquisitions in the last 3-4 years including 2 dermatology assets
attend investor conferences, conduct annual shareholder day, get coverage from 5 diverse analyst firms.
3. EU market needs to be exploited
4. Why the bitter fight to retain Iliana and Biran when ISS and Glass lewis had recommended vote against them and many shareholders including me said they have lost their trust to serve us.
5. Finally you need to morally answer the question asked by some shareholders. Just provide the real identification of the very altruistic people that voted for Iliana and Biran.
Pls stop obsessing on "how the heck can sun increase its ownership in taro". Intentions are everything...ultimately your actions just follow intentions.
Do the right thing for shareholders. And shareholders will appreciate you and thank you in public from their hearts.